Patents Represented by Attorney, Agent or Law Firm Kathryn A. Anderson
  • Antibodies to interleukin-4 receptors and uses thereof
    Patent number: 6716587
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: April 6, 2004
    Assignee: Immunex Corporation
    Inventors: Bruce A. Mosley, David J. Cosman, Linda S. Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Receptor that binds trail
    Patent number: 6642358
    Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.
    Type: Grant
    Filed: May 25, 2000
    Date of Patent: November 4, 2003
    Assignee: Immunex Corporation
    Inventors: Charles Rauch, Henning Walczak
  • Receptor that binds trail
    Patent number: 6569642
    Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.
    Type: Grant
    Filed: March 27, 2000
    Date of Patent: May 27, 2003
    Assignee: Immunex Corporation
    Inventors: Charles Rauch, Henning Walczak
  • Interleukin-4 receptors
    Patent number: 6548655
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 15, 2003
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Antibodies directed against trail
    Patent number: 6521228
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: April 2, 2001
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Polynucleotides encoding cytokine designated LERK-5
    Patent number: 6492140
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: January 3, 2001
    Date of Patent: December 10, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Cytokine designated lerk-5
    Patent number: 6479459
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: October 29, 1996
    Date of Patent: November 12, 2002
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • DNA encoding interleukin-4 receptors
    Patent number: 6391581
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: May 21, 2002
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • LERK-5 DNA
    Patent number: 6303769
    Abstract: LERK-5 polypeptides are disclosed, along with DNA sequences, vectors and transformed host cells useful in producing LERK-5. The LERK-5 polypeptides bind to elk and to hek, which are members of the eph/elk family of receptor tyrosine kinases.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: October 16, 2001
    Assignee: Immunex Corporation
    Inventors: Douglas P. Cerretti, Pranhitha Reddy
  • Cytokine that induces apoptosis
    Patent number: 6284236
    Abstract: A novel cytokine designated TRAIL induces apoptosis of certain target cells, including cancer cells and virally infected cells. Isolated DNA sequences encoding TRAIL are disclosed, along with expression vectors and transformed host cells useful in producing TRAIL polypeptides. Antibodies that specifically bind TRAIL are provided as well.
    Type: Grant
    Filed: May 26, 1999
    Date of Patent: September 4, 2001
    Assignee: Immunex Corporation
    Inventors: Steven R. Wiley, Raymond G. Goodwin
  • Cytokines that bind the cell surface receptor Hek
    Patent number: 6274117
    Abstract: Hek ligand (hek-L) polypeptides as well as DNA sequences, vectors and transformed host cells useful in providing hek-L polypeptides. The hek-L polypeptides bind to a cell surface receptor (hek) that is a member of the receptor tyrosine kinase family. Hek is expressed on cells that include certain tumor cell lines. The hek-L polypeptides also bind a distinct receptor tyrosine kinase known elk.
    Type: Grant
    Filed: July 21, 1999
    Date of Patent: August 14, 2001
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • CD30 ligand oligomers and polypeptides
    Patent number: 6143869
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Grant
    Filed: May 15, 1998
    Date of Patent: November 7, 2000
    Assignee: Immunex Corporation
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Receptor that binds trail
    Patent number: 6072047
    Abstract: A protein designated TRAIL receptor binds the protein known as TNF-Related Apoptosis-Inducing Ligand (TRAIL). The TRAIL receptor finds use in purifying TRAIL or inhibiting activities thereof. Isolated DNA sequences encoding TRAIL-R polypeptides are provided, along with expression vectors containing the DNA sequences, and host cells transformed with such recombinant expression vectors. Antibodies that are immunoreactive with TRAIL-R are also provided.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: June 6, 2000
    Assignee: Immunex Corporation
    Inventors: Charles Rauch, Henning Walczak
  • Fas antagonists
    Patent number: 6015559
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: January 18, 2000
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Antibodies that bind hek ligands
    Patent number: 5969110
    Abstract: Antibodies specific for a hek-L may be generated, using a hek-L polypeptide or fragment thereof as an immunogen. The antibodies may be monoclonal.
    Type: Grant
    Filed: April 8, 1998
    Date of Patent: October 19, 1999
    Assignee: Immunex Corporation
    Inventors: M. Patricia Beckmann, Douglas P. Cerretti
  • DNA encoding interleukin-4 receptors
    Patent number: 5856296
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 5, 1999
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Fas antagonists and uses thereof
    Patent number: 5830469
    Abstract: The present invention provides a panel of monoclonal antibodies and binding proteins which specifically bind to human Fas antigen. Some of the antibodies and binding proteins are capable of stimulating T cell proliferation, inhibiting binding of anti-Fas CH-11 monoclonal antibody to cells expressing Fas antigen, blocking anti-Fas CH-11 monoclonal antibody-mediated lysis of cells, and blocking Fas ligand-mediated lysis of cells. The invention also provides for therapeutic compositions comprising the monoclonal antibodies.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: November 3, 1998
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Mark R. Alderson
  • Antibodies immunoreactive with leukemia inhibitory factor receptors
    Patent number: 5785967
    Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, and antibodies that are immunoreactive with LIF-R are disclosed.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: July 28, 1998
    Assignee: Immunex Corporation
    Inventors: David P. Gearing, Patricia M. Beckmann
  • Receptor for oncostatin M
    Patent number: 5783672
    Abstract: A novel polypeptide functions as the .beta. chain of an oncostatin M receptor and is thus designated OSM-R.beta.. Heterodimeric receptor proteins comprising OSM-R.beta. and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.
    Type: Grant
    Filed: September 12, 1994
    Date of Patent: July 21, 1998
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman
  • DNA encoding type-I interleukin-I receptor-like protein designated 2F1
    Patent number: 5776731
    Abstract: 2F1 polypeptides members of the IL-1 receptor family are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: July 7, 1998
    Assignee: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims